Take cancer from uncertainty to insight

Expanded portfolio enables comprehensive genomic profiling from blood and tissue

TruSight Oncology 500 Product Family

The TruSight Oncology 500 product family enables comprehensive genomic profiling (CGP) from both blood and tissue biopsy samples in house. All three assays in the family are designed to identify key biomarkers in guidelines in clinical trials.

Learn More from the Experts

Learn how experts across the world have been benefiting from implementing TSO500 assays to enable in-house comprehensive genomic profiling from tissue and liquid biopsies.

Access Webinars
Our Products Have an Important Story to Tell
TruSight Oncology 500 TruSight Oncology 500 High-Throughput TruSight Oncology 500 ctDNA
FFPE (DNA and RNA) FFPE (DNA and RNA) Plasma (cfDNA)
523 genes for DNA variants 523 genes for DNA variants 523 genes for DNA variants
55 genes for RNA variants 55 genes for RNA variants  
Variants called:
SNVs
InDels
CNVs
Fusions
Splice variants
Variants called:
SNVs
InDels
CNVs
Fusions
Splice variants
Variants called:
SNVs
InDels
CNVs
Fusions (from DNA)
Panel size:
1.94Mb DNA; 358kb RNA
Panel size: 1.94Mb DNA; 358kb RNA Panel size: 1.94Mb DNA;
Sequencing Platforms:
NextSeq 550Dx (in Research Mode)
NextSeq 500/550
Sequencing Platforms:
NovaSeq 6000
Sequencing Platforms:
NovaSeq 6000
Sample Batching:
8 samples/run
Sample Batching:
16 – 192 samples/run
Sample Batching:
8-24 samples/run
Sample input:
40ng DNA
40ng RNA
Sample input:
40ng DNA
40-80ng RNA
Sample input:
30ng cfDNA
Specificity:
99.9998%
Specificity:
99.9998%
Specificity:
99.9995%
Sensitivity:
>96%
Sensitivity:
>96%
Sensitivity:
>95%
Detection of currently relevant DNA & RNA* variants for multiple types of cancer. Some key biomarkers include:
NTRK1        NTRK2        NTRK3        MSI        TMB (Emerging)
Lung Melanoma Colon Ovarian Breast Gastric Bladder Myeloid Sarcoma
AKT1 BRAF AKT1 BRAF AKT1 BRAF MSH5 ABL1 ALK
ALK CTNNB1 BRAF BRCA1 AR KIT PMS2 ASX1 APC
BRAF GNA11 HRAS BRCA2 BRCA1 KRAS TSC1 CALR BRAF
DDR2 GNAQ KRAS KRAS BRCA2 MET   CEBPA CDK4
EGFR KIT MET PDGFRA ERBB2 MLH1   ETV6 CTNNB1
ERBB2 MAP2K1 MLH1 FOXL2 FGFR1 PDGFRA   EZH2 ETV6
FGFR1 NF1 MSH2 TP53 FGFR2 TP53   FLT3 EWSR1
FGFR3 NRAS MSH6   PIK3CA     GATA2 FOXO1
KRAS PDGFRA NRAS   PTEN     IDH1 GLI1
MAP2K1 PIK3CA PIK3CA         IDH2 KJT
MET PTEN PMS2         JAK2 MDM2
NRAS TP53 PTEN         KIT MYOD1
PIK3CA   SMAD4         MPL NAB2
PTEN   TP53         NPM1 NF1
RET             RUNX1 PAX3
TP53             SF3B1 PAX7
TMB             SRSF2 PDGFRA
              TP53 PDGFRB
                SDHB
                SDHC
                SMARCB1
                TFE3
                WT1

The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on this page.

* The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.

TruSight Oncology 500 Product Family

Analytical Evaluation & Verification Service

The TruSight Oncology 500 Analytical Evaluation Service is a set of tools intended to guide you in aligning with the latest CAP, AMP, and European standards. We provide recommendations to help you evaluate analytical performance characteristics and integrate products into your workflows.

View Service
Illumina NGS Methods Guide

Liquid Biopsy Offers Advantages in the Modern Age
Liquid Biopsy Offers Advantages in the Modern Age

Innovations in molecular assays enable comprehensive, precise analysis of cell-free DNA.

Read Application Spotlight
Findings from Early Access Program
Findings from Early Access Program

The next step in precision medicine lies in decentralizing comprehensive biomarker testing.

Read Article
A Look at Circulating Tumor DNA in Liquid Biopsy Testing<
AMP 2019: A Look at Circulating Tumor DNA in Liquid Biopsy Testing

TruSight Oncology 500 ctDNA assists in detecting low levels of variants in circulating tumor DNA.

Access Webinar to Learn More
NTRK Fusion Detection for Identification of Rare Genomic Events
NTRK Fusion Detection for Identification of Rare Genomic Events

NTRK fusions are rare but important biomarkers linked to response to new TRK inhibitors. Watch CMO Phil Febbo and Maude Champagne walk through these advances in fusion detection.

Access Webinar
TruSight Oncology Family Grows with Liquid Biopsy and High-Throughput Assays

Now providing customers with a versatile, scalable, sample-to-report workflow.

Read More
TruSight Oncology 500 Selected to Power Liquid Biopsy Studies

Illumina and the Frederick National Laboratory are working together to establish clinical utility for liquid biopsies.

Read Article
The Unifying Force Has Arrived

TruSight Oncology 500 products offer deep, comprehensive, and accessible sequencing power for detecting tumor biomarkers.

Read Article
Have questions about our products? Connect with an Illumina representative.